All Stories

C4 Therapeutics halts BRAF degrader work to save cash for cemsidomide

C4 Therapeutics is continuing to saw off parts of its pipeline, this time ending work on its clinical-stage BRAF degraded program in order to focus on its IKZF1/3 degrader cemsidomide.

May 8, 2025 - 23:17
 0
C4 Therapeutics halts BRAF degrader work to save cash for cemsidomide
C4 Therapeutics is continuing to saw off parts of its pipeline, this time ending work on its clinical-stage BRAF degraded program in order to focus on its IKZF1/3 degrader cemsidomide.
Read More

Tags:

Previous Article

Neurocrine hands back 2 CNS gene therapy programs to Voyager

Next Article

Trump's new executive order targets gain-of-function research, citing unsupporte...

Related Posts

Caribou cuts 32% of staff, further purges pipeline to focus on 2 oncology CAR-T prospects

Caribou cuts 32% of staff, further purges pipeline to f...

Apr 25, 2025  0

The next generation of pulsed field ablation takes the stage at HRS annual meeting

The next generation of pulsed field ablation takes the ...

Apr 27, 2025  0

Lowering blood pressure reduces dementia risk in patients with hypertension, large China trial reveals

Lowering blood pressure reduces dementia risk in patien...

Apr 24, 2025  0